BridgeBio Pharma Long Term Debt 2018-2024 | BBIO

BridgeBio Pharma long term debt from 2018 to 2024. Long term debt can be defined as the sum of all long term debt fields.
BridgeBio Pharma Annual Long Term Debt
(Millions of US $)
2023 $1,727
2022 $1,708
2021 $1,704
2020 $476
2019 $92
2018 $55
2017 $
BridgeBio Pharma Quarterly Long Term Debt
(Millions of US $)
2024-09-30 $1,719
2024-06-30 $1,718
2024-03-31 $1,716
2023-12-31 $1,727
2023-09-30 $1,721
2023-06-30 $1,719
2023-03-31 $1,713
2022-12-31 $1,708
2022-09-30 $1,699
2022-06-30 $1,693
2022-03-31 $1,708
2021-12-31 $1,704
2021-09-30 $1,375
2021-06-30 $1,374
2021-03-31 $1,361
2020-12-31 $476
2020-09-30 $472
2020-06-30 $467
2020-03-31 $461
2019-12-31 $92
2019-09-30 $75
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.260B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00